Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
Rhea-AI Summary
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn, Ph.D., will present a company overview at the 2026 BIO International Convention in San Diego.
The presentation is scheduled for Wednesday, June 24, 2026, at 2:15 p.m. PT in Theater 3 at the San Diego Convention Center, with additional investor and partner meetings planned.
Positive
- None.
Negative
- None.
News Market Reaction – VANI
In the Jun 23 session, VANI gained 5.31%, reflecting a notable positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Conference appearance | Neutral | +0.8% | CEO presentation at Jefferies Global Healthcare Conference with webcast replay. |
| May 13 | Earnings update | Positive | +3.5% | Q1 2026 results with cash runway into 2027 and trial timing update. |
| Mar 26 | Earnings update | Positive | -1.9% | Q4 and 2025 results with GLP‑1 implant progress and extended funding. |
| Jan 29 | Clinical data | Positive | +1.3% | Cortigent Orion six-year feasibility data showing durable device function and safety. |
| Jan 27 | Equity offering | Negative | +8.0% | Registered direct and private placement equity raise including insider participation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
VANI has generally reacted modestly positively to conferences and updates, with occasional divergences around earnings and financing events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the 2026 BIO International Convention taking place this week in San Diego, California.
Details of Dr. Mendelsohn’s presentation are as follows:
Date: Wednesday, June 24, 2026
Time: 2:15 p.m. Pacific Time
Location: Theater 3, San Diego Convention Center
More information about the 2026 BIO International Convention can be found at https://convention.bio.org/.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development thereof, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. There may be additional risks that the Company consider immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 26, 2026. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462
